Browse Studies — Arctuva

Phase 2

A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction (VALOR)

This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 …

Heart FailureLeft Ventricular Systolic Dysfunction

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT05714085

Phase 3

A Phase 3, Single-arm, Open-label Extension Study to Evaluate the Safety of Finerenone in Addition to Standard of Care, in Pediatric Heart Failure Patients, From Birth to 18 Years of Age, With Left Ventricular Systolic Dysfunction (LVSD)

Researchers are looking for a better way to treat children and young adults who have heart failure with left ventricular systolic dysfunction (LVSD). Heart fai…

Left Ventricular Systolic DysfunctionHeart Failure (Pediatric)

Estimated

~$10 – $7,500

BayerNCT07192952

Phase 3

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Investigate the Efficacy, Safety, and PK/ PD of Finerenone, in Addition to Standard-of-care, in Pediatric Patients, 6 Months to < 18 Years of Age With Heart Failure (HF) and Left Ventricular Systolic Dysfunction (LVSD)

Researchers are looking for a better way to treat children who have heart failure with left ventricular systolic dysfunction (LVSD). Heart failure is a serious…

Left Ventricular Systolic DysfunctionHeart Failure (Pediatric)

Estimated

~$10 – $7,500

BayerNCT07188805

Multimodality Evaluation of Left Ventricular Remodeling In Mitral Regurgitation: A Pilot Study

The purpose of this research is to determine the feasibility of a larger, future study proposing a multimodal approach using cardiac CT and MRI to assess the r…

Left Ventricular Systolic Dysfunction

Estimated

~$10 – $750

Mayo ClinicNCT06770062